汪俊 博士
上海开运电竞 医药股份有限公司生物部副总裁

汪俊医生生高中毕业于重庆复旦本科社会本科社会，在东南亚神户本科社会获氧分子怪物学和怪物理学医生生学位学历，在瑞典达拉斯沧州本科社会西北生物技术学公司的药剂学系做完了医生生后设计。汪医生生在瑞典沧州本科社会西北生物技术学公司的和华盛顿本科社会扮演了5年讲师授；在默沙东公司的（Merck）任务了9年，扮演研究总提供人；在Nature、Science等全威科学性自媒体上投稿频繁篇小论文和实用新型，日前聘任于两个世界论文期刊的编委。做新抗茵素--平板电脑霉素团结板电脑素的出现 人，汪医生生曾特邀在英国剑桥本科社会和贵族生物技术会等多名府及科技创新机购参与科研主题演讲。20多年汪俊医生生成为美迪西，扮演怪物产品开发部的高级副总裁大人裁。

牛俊奇 博士
吉林大学第一医院肝病中心主任

主人职业医师，讲师，中医学界界硕士生探究生,硕士生探究生生指导者，政府发改委层次性津贴补贴领域专业团队。辽源市市高中转成中医学界界探究院副校长, 辽源市市省肝问题探究所局长，辽源市市高中1医生肝胆胰中医内科主人，辽源市市高中1医生临床护理实验药理学单位主人，辽源市市高中1医生患上性问题原因心中主人，《临床护理实验肝胆病期刊自媒体》小编，我们合理院沪巴斯德探究所和北华高中聘用讲师，辽源市市省肝炎病症学到理事会会主人理事会，辽源市市省傳感染学到声誉主人理事会，亚洲区及永安洋地域肝问题学到免费用户，欧洲地区肝问题学到免费用户，美利坚肝问题学到免费用户。并担当内部外十余家期刊自媒体的编委理事会，近来来在Hepatology，J Gastroenterol. Antiviral Res.  J Med Virol.等说出SCI查找的文献资料四十几个篇。较高影响力要素11.665。时间顺序承担起了“五一五”、“12五”政府新材料技术信息大量专向、863、973、政府自然生态合理基金、期货、现货、微盘等多选科研开发好项目。喜欢病毒码性肝炎病症,、另外各样肝问题、化解问题的原因及诊治。获卫生监督部有凸出贡献率中的青年领域专业团队、辽源市市省力荐高级的领域专业团队、中華中医学界界新材料技术信息2等奖、辽源市市高中白求恩四大中医专家等荣誉感头衔。

Qun (Max) Dang, Ph.D.
Principal Scientist, Exploratory Chemistry
Merck Research Laboratories

Qun (Max) Dang obtained his B.S. degree in chemistry in 1985 from Jilin University and Ph.D. in chemistry from Purdue University in 1992 (under a CGP scholarship).  Max joined Gensia pharmaceuticals (later became Metabasis) in 1992 and worked until 2009 with his last position as director of medicinal chemistry. In 2009, Max joined the External Basic Research department of Merck Rahway site as a Senior Investigator; from 2011 to 2013, he was a Director of External Medicinal Chemistry based in Shanghai and currently he is a Principal Scientist of Exploratory Chemistry department at the Kenilworth site.During his time at Metabasis, Max managed multiple drug discovery projects primarily in metabolic disease areas such as diabetes and dyslipidemia (such as FBPase inhibitors, glucagon antagonists, glucokinase activators, and AMPK activators). He also conducted researches in liver related disease such as hepatitis B, hepatitis C, liver cancer, liver fibrosis. Max's work at Metabasis led to two NCEs advancing to phase IIb clinical trials as potential treatment of type 2 diabetes.Since joining Merck in 2009, Max managed several integrated drug discovery projects carried out at various CROs in the areas of infectious disease and endocrine. His research interests include medicinal chemistry via rational drug design, heterocyclic chemistry, prodrugs, and nucleoside chemistry. Dr. Dang has authored or co-authored 84 publications in peer-reviewed journals, 2 book chapters, and 50 granted patents and applications.

联系我们：

邮箱：marketing@czchengteng.com

电话: +86 (21) 5859-1500（总机）